Deep Track Capital, LP reported 63 positions worth $6.48B for the quarter ended Jun 30, 2026, up 53.3% on the prior quarter. It opened 18 new positions, added to 20, trimmed 15 and exited 9. Its largest holding is Guardant Health, Inc. at 7.9% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Trade Value | Weight |
|---|---|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. | +825.0K | $248.35M | 3.83% |
| MANE Veradermics, Inc | +1.50M +300.0% | $184.41M | 3.79% |
| COAG Hemab Therapeutics Holdings, Inc. | +3.60M | $132.30M | 2.04% |
| BMRN Biomarin Pharmaceutical Inc | +2.16M +187.6% | $123.45M | 2.92% |
| GHRS GH Research PLC | +3.33M | $89.60M | 1.38% |
| UTHR UNITED THERAPEUTICS Corp | +123.6K | $66.98M | 1.03% |
| AVTX Avalo Therapeutics, Inc. | +3.61M | $66.71M | 1.03% |
| CLDX Celldex Therapeutics, Inc. | +1.66M +128.9% | $61.59M | 1.69% |
| ALT Altimmune, Inc. | +19.25M | $58.52M | 0.903% |
| GMAB Genmab A/S | +1.99M +54.2% | $54.58M | 2.39% |
| Holding | Change | Trade Value | Weight |
|---|---|---|---|
| AXSM Axsome Therapeutics, Inc. | -400.0K -36.4% | $97.91M | 2.64% |
| IMVT Immunovant, Inc. | -2.19M -19.0% | $84.22M | 5.55% |
| BBIO BridgeBio Pharma, Inc. | -841.4K -100.0% | $62.49M | Exited |
| CYTK Cytokinetics Inc | -674.3K -49.1% | $57.45M | 0.92% |
| MBX MBX Biosciences, Inc. | -1.03M -37.2% | $56.58M | 1.48% |
| IMCR Immunocore Holdings plc | -1.62M -83.9% | $51.46M | 0.152% |
| GERN Geron Corp | -31.72M -100.0% | $47.26M | Exited |
| ANIP Ani Pharmaceuticals Inc | -600.0K -100.0% | $46.14M | Exited |
| ENGN enGene Therapeutics Inc. | -4.38M -100.0% | $29.81M | Exited |
| JANX Janux Therapeutics, Inc. | -1.19M -100.0% | $16.50M | Exited |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. | +825.0K | $248.35M | 3.83% |
| COAG Hemab Therapeutics Holdings, Inc. | +3.60M | $132.30M | 2.04% |
| GHRS GH Research PLC | +3.33M | $89.60M | 1.38% |
| UTHR UNITED THERAPEUTICS Corp | +123.6K | $66.98M | 1.03% |
| AVTX Avalo Therapeutics, Inc. | +3.61M | $66.71M | 1.03% |
| ALT Altimmune, Inc. | +19.25M | $58.52M | 0.903% |
| WGS GeneDx Holdings Corp. | +700.0K | $48.06M | 0.741% |
| HROW Harrow, Inc. | +969.0K | $41.15M | 0.635% |
| IMMX Immix Biopharma, Inc. | +2.78M | $28.61M | 0.441% |
| STTK Shattuck Labs, Inc. | +3.71M | $25.72M | 0.397% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| BBIO BridgeBio Pharma, Inc. | -841.4K | $62.49M | 1.48% |
| GERN Geron Corp | -31.72M | $47.26M | 1.12% |
| ANIP Ani Pharmaceuticals Inc | -600.0K | $46.14M | 1.09% |
| ENGN enGene Therapeutics Inc. | -4.38M | $29.81M | 0.705% |
| JANX Janux Therapeutics, Inc. | -1.19M | $16.50M | 0.39% |
| CBIO Crescent Biopharma, Inc. | -453.7K | $8.33M | 0.197% |
| LRMR Larimar Therapeutics, Inc. | -1.50M | $6.75M | 0.16% |
| HELP Helus Pharma Inc. | -1.31M | $6.30M | 0.149% |
| BLLN BillionToOne, Inc. | -50.0K | $3.95M | 0.093% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | GH Guardant Health, Inc. | Healthcare | 3.39M | $509.10M | 7.86% | +55.1K | +1.6% | Added | 2.54% |
| 2 | IMVT Immunovant, Inc. | Healthcare | 9.34M | $359.91M | 5.55% | -2.19M | -19.0% | Reduced | 4.53% |
| 3 | GPCR Structure Therapeutics Inc. | Healthcare | 4.74M | $254.40M | 3.93% | +460.2K | +10.8% | Added | 2.17% |
| 4 | PCVX Vaxcyte, Inc. | Healthcare | 4.30M | $249.96M | 3.86% | 0 | 0.0% | Unchanged | 2.97% |
| 5 | ALNY Alnylam Pharmaceuticals, Inc. | Healthcare | 825.0K | $248.35M | 3.83% | +825.0K | – | New | 0.62% |
| 6 | MANE Veradermics, Inc | Healthcare | 2.00M | $245.88M | 3.79% | +1.50M | +300.0% | Added | 4.79% |
| 7 | TARS Tarsus Pharmaceuticals, Inc. | Healthcare | 3.67M | $230.79M | 3.56% | +66.8K | +1.9% | Added | 8.45% |
| 8 | ALKS Alkermes plc. | Healthcare | 4.00M | $209.58M | 3.23% | +409.7K | +11.4% | Added | 2.39% |
| 9 | OCUL Ocular Therapeutix, Inc | Healthcare | 19.69M | $193.32M | 2.98% | 0 | 0.0% | Unchanged | 8.75% |
| 10 | BMRN Biomarin Pharmaceutical Inc | Healthcare | 3.31M | $189.25M | 2.92% | +2.16M | +187.6% | Added | 1.71% |
| 11 | NRIX Nurix Therapeutics, Inc. | Healthcare | 7.74M | $187.69M | 2.9% | +1.39M | +21.9% | Added | 6.96% |
| 12 | ORKA Oruka Therapeutics, Inc. | Healthcare | 1.93M | $183.30M | 2.83% | -108.2K | -5.3% | Reduced | 3.06% |
| 13 | ALMS Alumis Inc. | Healthcare | 6.35M | $178.65M | 2.76% | -424.0K | -6.3% | Reduced | 4.97% |
| 14 | IONS Ionis Pharmaceuticals Inc | Healthcare | 2.20M | $174.44M | 2.69% | +250.0K | +12.8% | Added | 1.33% |
| 15 | CMPS COMPASS Pathways plc | Healthcare | 12.16M | $172.09M | 2.66% | 0 | 0.0% | Unchanged | 8.96% |
Tip. Select a row to see that position’s full history at Deep Track Capital.
As of its Q2 2026 13F filing, Deep Track Capital, LP’s five largest positions were Guardant Health, Inc. (GH) at 7.9%, Immunovant, Inc. (IMVT) at 5.6%, Structure Therapeutics Inc. (GPCR) at 3.9%, Vaxcyte, Inc. (PCVX) at 3.9%, Alnylam Pharmaceuticals, Inc. (ALNY) at 3.8% of the reported portfolio.
Deep Track Capital, LP reported a 13F portfolio worth $6.48B across 63 positions for Q2 2026. That is up 53.3% from the previous quarter.
Its largest purchases by value were Alnylam Pharmaceuticals, Inc. ($248.35M), Veradermics, Inc ($184.41M), Hemab Therapeutics Holdings, Inc. ($132.30M). It opened 18 new positions.
Its largest sales by value were Axsome Therapeutics, Inc. ($97.91M), Immunovant, Inc. ($84.22M), BridgeBio Pharma, Inc. ($62.49M). It exited 9 positions entirely.
From the Form 13F-HR reports Deep Track Capital, LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.